AlzeCure Pharma
12.8.2021 16:32:43 CEST | ACCESS Newswire | Press release
STOCKHOLM, SWEDEN / ACCESSWIRE / August 12, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that an abstract about the neurology platform NeuroRestore, its link to BDNF/TrkB signalling and potential therapeutic role in depression, has been accepted for presentation at the ECNP 2021 conference, which this year will be held in Lisbon, Portugal, on October 2-5.
The abstract, titled Characterization of positive allosteric modulators of TrkB for the treatment of depression, will be presented at the major international conference European College of Neuropsychopharmacology (ECNP) 2021, by Dr. Johan Sandin, Chief Scientific Officer at AlzeCure. Other authors include Dr. Pontus Forsell, Head of Discovery, Dr. Gunnar Nordvall, Head of Chemistry, and Magnus Halldin, Head of DMPK & Safety at AlzeCure.
The presentation includes results from studies that show how substances from the NeuroRestore project have had potent effects in various preclinical models linked to depression. Furthermore, the results show that these substances bind to the receptors for the neurotrophin BDNF, so called TrkB receptors, and stimulate the signaling of this system. This biological system has been linked to depression, and the support for this hypothesis has recently been further strengthened, and new scientific findings indicate that many of the classic antidepressant drugs available today actually mediate their effect via BDNF/TrkB.*
"These data demonstrate the impressive width of the NeuroRestore platform and the various indications that may be applicable to this unique biological mechanism," said Johan Sandin, CSO at AlzeCure Pharma.
"The NeuroRestore platform, with ACD856 as the leading clinical candidate drug, is based on a strong scientific foundation and the approval of our abstract is a clear validation of our research and strengthens our conviction that our studies are at the forefront of research identifying several potential opportunities," said Martin Jönsson, CEO of AlzeCure Pharma.
*) Casarotto et al., Antidepressant drugs act by directly binding to TRKB neurotrophin receptors, Cell 184, 1299-1313, March 4, 2021, https://www.cell.com/cell/pdf/S0092-8674(21)00077-5.pdf
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep disorders, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $10 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Attachments
AlzeCure to present abstract at ECNP conference on NeuroRestore project's potential in depression
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/659487/AlzeCure-to-Present-Abstract-at-ECNP-Conference-on-NeuroRestore-Projects-Potential-in-Depression
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Study Finds Lower Rates of Overweight Among Vegan-Fed Cats23.10.2026 16:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats fed either conventional meat-based (90%) or vegan (10%) diets for at least one year. After accounting for factors including age, sex, neuter status, activity and feeding practices, vegan-fed cats had 34% lower odds of being assessed as overweight. However, the difference was not statistically significant, in part reflecting the relatively small number of vegan-fed cats. For several body weight-related problems, no vegan-fed cats were affected. Nevertheless, researchers say the findings show an interesting trend that warrants further investigation. Overweight and obesity are common in domestic cats, with veterinary studies estimating that around 30-60% of cats are overw
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award23.10.2026 16:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications. The judging panel cited MCM's innovation that achieves affordable, premium-level comfort for mid-class vehicle programs. About Leggett Dynamics' Mid-Class Massage System Leggett Dynamics' MCM is a comfort innovation that expands premium massage technology beyond the luxury vehicle segment. Already in serial production with a leading global OEM and generating strong interest from multiple global automakers, the innovation delivers a premium massage experience while reducing system cost and complexity through the intelligent use of pre
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
Karbon-X (OTCQB:KARX) Accelerates High-Margin Transformation in Q1 FY2027: Gross Margin Expands to 32%, Operating Cash Burn Drops 55%, and Deferred Revenue Reaches $4.3 Million22.10.2026 13:45:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced its financial and operational results for the first quarter of fiscal 2027 (ended August 31, 2026), following the filing of its Quarterly Report on Form 10-Q. The quarter was highlighted by a significant expansion in gross margin to 32%, a 55% reduction in net operating cash use, and continued momentum across international project development and advisory engagements. Through disciplined execution, Karbon-X has shifted its commercial mix toward higher-margin, value-added environmental consulting and project commercialization, strengthening its operational foundation for sustainable, long-term growth. First Quarter Fiscal 2027 HighlightsSubstantial Gross Margin Expansion: Gross margin rose to 32%, compared with 0.8% in the prior-year period, reflecting a higher-margin revenue mix centered on technical advisory an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom